Your browser doesn't support javascript.
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.
Terao, Toshiki; Yamashita, Takeshi; Fukumoto, Ami; Kamura, Yuya; Ikeda, Daisuke; Kuzume, Ayumi; Tabata, Rikako; Tsushima, Takafumi; Miura, Daisuke; Narita, Kentaro; Takeuchi, Masami; Doi, Masahiro; Umezawa, Yuka; Otsuka, Yoshihito; Takamatsu, Hiroyuki; Matsue, Kosei.
  • Terao T; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Yamashita T; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
  • Fukumoto A; Division of Internal Medicine, Keiju Kanazawa Hospital, Ishikawa, Japan.
  • Kamura Y; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Ikeda D; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Kuzume A; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Tabata R; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Tsushima T; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Miura D; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Narita K; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Takeuchi M; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Doi M; Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-cho, Kamogawa, Chiba, 296-8602, Japan.
  • Umezawa Y; Department of Clinical Laboratory, Kameda Medical Center, Kamogawa, Japan.
  • Otsuka Y; Department of Clinical Laboratory, Kameda Medical Center, Kamogawa, Japan.
  • Takamatsu H; Department of Clinical Laboratory, Kameda Medical Center, Kamogawa, Japan.
  • Matsue K; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan. takamaz@staff.kanazawa-u.ac.jp.
Int J Hematol ; 115(5): 737-747, 2022 May.
Article in English | MEDLINE | ID: covidwho-1990778
ABSTRACT
We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multiple myeloma (MM)] were evaluated. Seropositivity was observed in 88.7% and a clinically protective titer in 38.3% of MM patients, both of which were significantly lower than those of healthy controls. Patients receiving anti-CD38 antibodies had much lower antibody titers, but antibody titers recovered in those who underwent a wash-out period before vaccine administration. Older age (≥65), anti-CD38 antibody administration, immunomodulatory drugs use, lymphopenia (<1000/µL), and lower polyclonal IgG (<550 mg/dL) had a negative impact for the sufficient antibody production according to multivariate analysis. Patients with clinically protective titer had a significantly higher number of CD19+ lymphocytes than those with lower antibody responses (114 vs. 35/µL, p = 0.016). Our results suggested that patients with PCD should be vaccinated, and that the ideal protocol is to temporarily interrupt anti-CD38 antibody therapy for a "wash-out" period of a few months, followed by a (booster) vaccine after the B-cells have recovery.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Multiple Myeloma Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int J Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: S12185-022-03300-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Multiple Myeloma Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Int J Hematol Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: S12185-022-03300-4